Gene

WT1

WT1 transcription factor

Explore in graph →CI-GENE-00038916HGNC:12796 ENSG00000184937 NCBI 7490 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (17)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–17 of 17 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ATF1 Fusion + FLI1 Fusion + WT1 FusionFLI1 WT1 ATF11
Trabectedin	Sarcoma	Predictive	B	Supports Sensitivity Response	2	submitted	EID12544 In a pooled analysis of two phase II studies (n = 66) of advanced translocation-related sarcoma, trabectedin (1.2 mg/m² q3w) produced median PFS 5.6 months (95% CI 4.1–7.3) and median OS 17.5 months (… (full text at CIViC) PMID 28526720 · Takahashi et al., 2017 · Open in CIViC	civic
WT1 Fusion4
(diagnostic)	Desmoplastic Small Round Cell Tumor	Diagnostic	B	Supports Positive	2	accepted	EID11405

Cohorts

Alteration frequency by cohort (71)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved71 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (7)

25 per page, newest first.

pubmedPublishedShowing 1–7 of 7 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
· Blood · 2009 · PMID 19221039 · validated civic_curation pubmed
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.
· J Clin Oncol · 2008 · PMID 18591546 · validated civic_curation pubmed
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
· J Clin Oncol · 2008 · PMID 18559874 · validated civic_curation pubmed
Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

WT1 Exon 7 Mutation9
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support N/A	4	accepted	EID163 Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AM… (full text at CIViC) PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support N/A	3	accepted	EID162 No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML. PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID203 Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD follo… (full text at CIViC) PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID204 WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients. PMID 18559874 · Paschka et al., 2008 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID205 WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML. PMID 18591546 · Virappane et al., 2008 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID206 WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML. PMID 18591546 · Virappane et al., 2008 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	2	accepted	EID201 Mutations in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML. PMID 19536888 · Renneville et al., 2009 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	2	accepted	EID202 Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence. PMID 19536888 · Renneville et al., 2009 · Open in CIViC	civic
Cytarabine + DaunorubicinCombination	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID139 WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML. PMID 18591546 · Virappane et al., 2008 · Open in CIViC	civic

WT1 Exon 7 Mutation9

(prognostic)

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Does Not Support N/A

accepted

EID163

Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AM… (full text at CIViC)

PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Does Not Support N/A

accepted

EID162

No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML.

PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID203

Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD follo… (full text at CIViC)

PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID204

WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.

PMID 18559874 · Paschka et al., 2008 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID205

WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML.

PMID 18591546 · Virappane et al., 2008 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID206

WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML.

PMID 18591546 · Virappane et al., 2008 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID201

Mutations in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.

PMID 19536888 · Renneville et al., 2009 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID202

Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence.

PMID 19536888 · Renneville et al., 2009 · Open in CIViC

civic

Cytarabine + DaunorubicinCombination

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Resistance

accepted

EID139

WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML.

PMID 18591546 · Virappane et al., 2008 · Open in CIViC

civic

WT1 Exon 9 Mutation2
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support N/A	4	accepted	EID165 Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AM… (full text at CIViC) PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID210 WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients. PMID 18559874 · Paschka et al., 2008 · Open in CIViC	civic

WT1 Exon 9 Mutation2

(prognostic)

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Does Not Support N/A

accepted

EID165

PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC

civic

〃

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID210

WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.

PMID 18559874 · Paschka et al., 2008 · Open in CIViC

civic

WT1 Mutations1
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	submitted	EID8563 WT1 mutations (documented across the protein) appear more frequently and impact new sites in childhood AML as compared to adult AML. The co-occurrence of a FLT3-ITD with WT1 mutations (and/or NUP98-NS… (full text at CIViC) PMID 29227476 · Bolouri et al., 2018 · Open in CIViC	civic

WT1 Mutations1

(prognostic)

Acute Myeloid LeukemiaCURATED_BROADER

Prognostic

Supports Poor Outcome

submitted

EID8563

WT1 mutations (documented across the protein) appear more frequently and impact new sites in childhood AML as compared to adult AML. The co-occurrence of a FLT3-ITD with WT1 mutations (and/or NUP98-NS… (full text at CIViC)

PMID 29227476 · Bolouri et al., 2018 · Open in CIViC

civic